PURPOSE: We evaluated the distribution and clinical impact of @entity470 , @entity984 and @entity1722 copy number gains and @entity470 , @entity984 and @entity817 activating mutations in resected @entity1149 ( @entity1149 ) from 151 Polish @entity1 . MATERIALS AND METHODS: Quantitative PCR and DNA sequencing were used for copy number evaluation and mutational analysis, respectively. RESULTS: An increased @entity470 CN was found in 21.2% of the @entity5 , more commonly of the non-squamous histology (P=0.029), larger in size (P=0.004) and those obtained from @entity1 (P=0.040). @entity1722 copy gain was observed in 21.8% of the @entity1 , more frequently with lymph node @entity3 (P=0.048) and stage IIIA disease (P=0.061). @entity984 gain was found in 29.3% of the @entity5 , and was not associated with @entity1 ' clinicopathological features. No @entity817 mutations were found. @entity470 and @entity984 mutation frequency and associations with clinicopathological characteristics did not differ significantly from those previously described for the NSCLC @entity1 of Caucasian ethnicity. Strong associations existed between most of the analyzed alterations. In the multivariate model, @entity470 mutations constituted an independent prognostic factor of the disease recurrence in @entity420 @entity1 (HR 7.20; 95%CI 1.31-39.48; P=0.023), while an increased @entity470 copy number tended to indicate a shorter overall survival (HR 4.85; 95%CI 0.92-25.58; P=0.062). CONCLUSIONS: @entity470 pathway genes alterations are frequent in @entity1149 from Polish @entity1 and have a prognostic potential for @entity1 ' clinical outcome after a curative @entity5 resection. Gene CN evaluation by quantitative PCR provides comparable results and enables assay standardization, yet the optimal scoring system needs to be developed.

Significance of XXXX signaling pathway genetic alterations in radically resected @entity1149 from a Polish cohort. One institutional study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLCs', 'non-small cell lung cancers'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity470 :: (1956,Gene) :: ['EGFR']
